Novo Nordisk’s Q4 results were in line with our expectations, but the disappointing guidance for 2017 sent the shares into jeopardy – plunged by more than 7% post the results announcement. NB all sales numbers are in local currencies (LC), unless specified otherwise. Q4 sales barely managed to grow by 3% in LC and 2% in DKK to DKK29.5bn, characterised by increasing competition and pricing pressure in the basal insulin market. Although the new generation insulin – Tresiba, Xu
03 Feb 2017
2017 outlook ruins the sentiment
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2017 outlook ruins the sentiment
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
03 Feb 2017 -
Author:
Kamla Singh -
Pages:
4
Novo Nordisk’s Q4 results were in line with our expectations, but the disappointing guidance for 2017 sent the shares into jeopardy – plunged by more than 7% post the results announcement. NB all sales numbers are in local currencies (LC), unless specified otherwise. Q4 sales barely managed to grow by 3% in LC and 2% in DKK to DKK29.5bn, characterised by increasing competition and pricing pressure in the basal insulin market. Although the new generation insulin – Tresiba, Xu